{
  "id": 3805797,
  "title": "Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models",
  "url": "https://urgent.news/2026/08/27/inhaled-suppressor-trna-restores-gene-function-in-cystic-fibrosis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T18:00:22.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/drug-discovery/inhaled-suppressor-trna-restores-gene-function-in-cystic-fibrosis-models/"
  },
  "original_language": "en",
  "account": "Researchers from the University of Toronto have developed an innovative RNA therapeutic strategy that may hold promise for treating various genetic diseases caused by specific mutations. Their approach involves chemically enhanced suppressor transfer RNAs (sup-tRNAs) paired with a targeted delivery system for the lungs. Sup-tRNAs assist in cells reading through premature stop signals in genetic instructions for protein production, enabling the generation of full-length, functional proteins.\n\nLed by Dr. Bowen Li, an associate professor in the Leslie Dan Faculty of Pharmacy at U of T, the research team engineered sup-tRNAs to facilitate the reading of premature stop codons in messenger RNA (mRNA). They then tested this method using bronchial epithelial cells, mouse models, and patient-derived cystic fibrosis organoids. Their findings indicated that the chemical modifications enhanced the readthrough of premature termination codons and tRNA aminoacylation, prolonged the functional activity of tRNAs, and reduced immune system activation. Crucially, the approach successfully restored production and functionality of the CFTR protein across cell, animal, and patient-derived organoid models.\n\nFurthermore, the researchers discovered that this approach can be combined with existing cystic fibrosis medications, indicating the potential for combination therapy. Dr. Li, also an affiliate scientist at the University Health Network’s Princess Margaret Cancer Centre, believes that this research could pave the way for a new class of drugs addressing a wide range of genetic diseases through a common therapeutic strategy.\n\nNonsense mutations, which introduce premature stop signals in mRNA, often result in truncated, nonfunctional proteins, disrupting vital functions in a manner that is challenging to treat. These mutations account for approximately 11% of human genetic disorders, and developing a separate gene therapy for each individual mutation is considered highly challenging. Suppressor tRNAs (sup-tRNAs) present a promising solution. By modifying their anticodons to recognize premature stop codons, engineered sup-tRNAs can insert the appropriate amino acid, allowing the cell to resume translation and produce full-length, functional proteins.\n\nHowever, the clinical potential of sup-tRNAs has been limited by inefficient readthrough, immunogenicity, and difficulties in delivering them to the body. To address these challenges, the researchers chemically modified sup-tRNAs and developed lipid nanoparticles (LNPs) for targeted lung delivery via inhalation. They aimed to repair the nonsense mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a primary cause of cystic fibrosis.\n\nCollaborative efforts were essential for this project, according to co-senior author Dr. Haissi Cui, assistant professor of chemistry in the Faculty of Arts & Science. Their interdisciplinary team utilized natural design principles, discovering that adding a specific modification increased the activity and longevity of engineered tRNAs. Co-lead author Jingan (Charles) Chen, a researcher in Dr. Li's lab, noted the challenge of delivering tRNAs to the targeted cells. They addressed this by creating a tailored lipid nanoparticle delivery system specifically designed for tRNA, emphasizing the importance of cargo-specific delivery in turning these tRNAs into potential therapeutic agents.\n\nThe study focuses on cystic fibrosis, a disease where cells fail to move salt and water, leading to mucus buildup in the airways and gut. Current treatments, such as CFTR modulators, are not effective for roughly one in 10 patients whose disease results from nonsense mutations. The U of T researchers evaluated the therapeutic efficacy of their sup-tRNA platform using cystic fibrosis as a disease model, examining not only the reappearance of the CFTR protein but also its activity.\n\nThrough their work, the researchers demonstrated that in human airway cells with common nonsense mutations, the sup-tRNA platform successfully restored production and functionality of the CFTR protein. These findings suggest that this RNA therapeutic strategy may hold broad applicability for treating a variety of genetic diseases caused by similar mutations, offering new hope for patients with few or no existing treatment options.",
  "summary": "A preclinical study showed how chemically enhanced suppressor tRNAs combined with a lung-targeted delivery system can restore production of a critical protein in models of cystic fibrosis caused by nonsense mutations. The post Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}